- In the largest study of its kind, less than half of patients prescribed the new class of cholesterol drugs, PCSK9 inhibitors, received insurance approval even if patients had atherosclerotic cardiovascular disease (plaque build-up of the arteries) or markedly elevated bad cholesterol.
- The most significant factor associated with approval was insurance type, with Medicare patients more likely to be approved than those with private insurance.
Embargoed until 4 a.m. CT / 5 a.m. ET Monday, October 30, 2017
DALLAS, October 30, 2017 — Less than half of patients received their insurer’s approval for prescriptions of PCSK9 inhibitors, according to new research in the American Heart Association’s journal Circulation.
PCSK9 inhibitors, like Repatha (evolocumab) and Praluent (alirocumab), work by increasing the removal of low-density lipoprotein (LDL) or “bad” cholesterol from the blood. They have been shown to reduce LDL by 60 percent and decrease major cardiac events but cost much more than other cholesterol-lowering drugs with an average cost of $14,300 per year. Prescriptions require prior authorization by health insurance companies.
In a nationwide review of the pharmacy claims combined with electronic medical records (EMRs) lab test results of 9,357 patients prescribed the drug between July 2015 and August 2016, 4,397 (47 percent) were approved for PCSK9 inhibitor therapy and 4,960 (53 percent) were rejected. Sixty percent of those patients had a history of atherosclerotic cardiovascular disease (plaque-buildup of the arteries) while 40 percent did not.
“With the controversy surrounding whether or not these drugs were cost effective, we were anticipating that there might be some reluctance by insurance companies to cover these medications,” said senior author Robert Yeh, M.D., director of the Smith Center for Outcomes Research in Cardiology at Beth Israel Deaconess Medical Center in Boston.
“However, we were surprised by the very high rate of rejection, even when prescribed to patients with known atherosclerotic cardiovascular disease, very high LDL levels and those who were intolerant of statins, for example,” he said.
Researchers also found that the most significant factor associated with approval rates was insurance type, with the lowest approval rates for private insurance and the highest approval for Medicare.
“Whether or not we can agree on the cost-effectiveness of these drugs, I believe most would agree that one’s access to medications should be driven primarily by the strength of the indications for the prescription as opposed to what drug plan you happen to carry,” said Yeh, who is also an Associate Professor of Medicine at Harvard Medical School. “Approximately 1 out of 3 patients who had their prescription approved did not purchase or receive the medication. Those patients who didn’t purchase their medication had an out-of-pocket cost that was twice as high as those who did purchase it,” said Dr. Gregory Hess, first study author and senior fellow of Health Economics at University of Pennsylvania and chief medical officer at Symphony Health.
“Approximately 1 out of 3 patients who had their prescription approved, did not purchase or receive the medication. Those patients who didn’t purchase their medication had an out-of-pocket cost that was more than twice as high as those who did purchase it,” said Gregory Hess, M.D., who is first author of the study and a Senior Fellow of Health Economics at University of Pennsylvania and Chief Medical Officer at Symphony Heath.
The findings are based on Symphony Health’s HIPPA-compliant patient-level data from all fifty states and all payer types.
“Better education for providers prescribing these medications and more uniform guidelines by insurers about what will and will not be covered are necessary to reduce the amount of administrative waste that is created to reject prescriptions for new medications,” Yeh said.
The study was a retrospective analysis and could not determine whether patients suffered any harm from the rejection of these prescriptions.
In addition to Drs Yeh and Hess, co-authors are Pradeep Natarajan, M.D., MM.Sc.; Kamil F. Faridi, M.D.; Anna Fievitz, B.S and Linda Valsdottir, M.S. Author disclosures are on the manuscript.
The National Heart, Lung and Blood Institute and the John S. LaDue Memorial Fellowship in Cardiology at Harvard University helped fund the authors involved in the study.
- Multimedia available on the right column of the release link: https://newsroom.heart.org/news/less-than-half-of-patients-prescribed-new-cholesterol-drug-receive-insurance-approval?preview=905c81f1d78be1ea9b59e8d1333a81bc
- After October 30, view the manuscript online.
- Information about cholesterol
- Follow AHA/ASA news on Twitter @HeartNews
- For updates and new science from the Circulation journal follow @CircAHA
Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association’s policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at www.heart.org/corporatefunding.
About the American Heart Association
The American Heart Association is devoted to saving people from heart disease and stroke – the two leading causes of death in the world. We team with millions of volunteers to fund innovative research, fight for stronger public health policies and provide lifesaving tools and information to prevent and treat these diseases. The Dallas-based association is the nation’s oldest and largest voluntary organization dedicated to fighting heart disease and stroke. To learn more or to get involved, call 1-800-AHA-USA1, visit heart.org or call any of our offices around the country. Follow us on Facebook and Twitter.
For Media Inquiries and AHA/ASA Spokesperson Perspective: 214-706-1173
Carrie Thacker: 214-706-1665; email@example.com
For Public Inquiries: 1-800-AHA-USA1 (242-8721)